EMA (EU)
GUIDANCE FINAL
Draft guideline on the requirements for demonstrating therapeutic equivalence for nasal products
Published: 10/8/2026Detected: 10/8/2026
Summary preview
Defines a stepwise, evidence-based framework for demonstrating therapeutic equivalence for nasal products with the same active moiety(ies), prioritizing in vitro data and using pharmacokinetics as a surrogate for local…
Get the full analysis, free
Create a free account to see the complete summary, key takeaways, and why this matters for your products, and to get alerts like this by email.
Create free accountrespiratory
pediatrics
immunology
#therapeutic equivalence
#nasal products
#bioequivalence
#pharmacokinetics
#systemic safety
Official Source Document Source Verified
Access the original document directly from EMA.
More from EMA (EU)
- Paediatric Committee (PDCO): 13-16 October 202610/13/2026
- Meeting of the Medicine Shortages Single Point of Contact (SPOC) Working Party10/13/2026
- EMA/FVE information session for veterinary students: the importance of pharmacovigilance10/13/2026
- Committee for Orphan Medicinal Products (COMP): 6-8 October 202610/12/2026
- Mandatory use of ISO/ICH E2B(R3) individual case safety reporting in the EU: hands-on training course using the EudraVigilance system10/12/2026